TAK-981 is a first-in-class inhibitor of the SUMOylation enzymatic cascade being developed for the treatment of multiple myeloma.

SparkCures ID 409
Developed By Takeda Oncology
Generic Name TAK-981
Treatment Classifications
  • SUMO-activating enzyme subunit 2 (SAE2)

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)


There are no resources, links or videos to display for this treatment.